| Author | Year | Level of evidence | Systemic treatment type | Total number of patients | Number of patients systemic treatment/No systemic treatment | Male/female | Average age in years (range) |
| Balke et al. [19] | 2010 | IV | Perioperative or postoperative or non-operative IV or oral bisphosphonates | 25 | 25/0 | 9/16 | 38.8 (15 - 75) |
| Chawla et al. [18] | 2013 | IV | Post-operative or non-operative RANK ligand antibody | 282 | 282/0 Cohort I—Surgically unsalvageable disease (n = 169) cohort II—Patients with planned surgery associated with severe morbidity (n = 101) cohort III—Patients in previous study of denosumab (n = 11) | 118/164 | 33.2 (24 - 45) |
| Totals | - | - | - | 307 | 307/0 | 127/180 | 33.7* (15 - 75) |